New drug shows promise for ulcerative colitis in early trial

This study tests a new medicine called SHR-1139 in 21 adults with moderate-to-severe ulcerative colitis, a condition that causes inflammation in the colon. The treatment has two parts: 12 weeks of induction therapy followed by 48 weeks of maintenance therapy. The main goal is to see if patients improve by week 12, with longer-term outcomes checked at week 60.